Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373274 | 0.83 | ALDH1A1 (0.50) | MAPTLMNANPSR1POLBCYP2C9 | |
| SCHEMBL4402699 | 0.81 | GPR55 (0.55) | CA2CA1MAPTLMNAVCAM1 | |
| SCHEMBL5322689 | 0.80 | MAPT (0.47) | MAPTLMNANPSR1POLBCYP2C9 | |
| E319 SCHEMBL6507343 | 0.79 | ALDH1A1 (0.53) | MAPTLMNANPSR1POLBCYP2C9 | |
| SCHEMBL785195 | 0.77 | HDAC8 (0.52) | LMNAPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL8144482 | 0.77 | ALDH1A1 (0.47) | CA2CA1MAPTLMNAVCAM1 | |
| SCHEMBL5914742 | 0.77 | MAPT (0.43) | MAPTLMNANPSR1POLBCYP2C9 | |
| SCHEMBL14720986 | 0.77 | MAPT (0.43) | MAPTLMNANPSR1POLBCYP2C9 | |
| SCHEMBL9731510 | 0.76 | GAA (0.57) | CA2CA1MAPTLMNAVCAM1 | |
| SCHEMBL13144873 | 0.76 | MAPT (0.46) | CA1MAPTLMNANPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | disclosed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| US-6653312-B1 | Such as 3-((3-((amino(2-thienyl)methylideneamino)-benzyl)-amino)-N-(1- methyl-2,3-dihydro-1H-indol-5-yl)propanamide; NO-synthase enzyme inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | CAPN1, CAPN2, CAPNS1 | CA2 77/4885CA1 1169/4885MAPT 1874/4885 |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS2, NOS1, NOS3 | CA2 1086/4885CA1 4504/4885MAPT 2048/4885 |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | ADM2, NUP155, ABCG2 | CA2 3804/4885CA1 4691/4885MAPT 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.